In vitro or in vivo experimentations focused in finding the PKCε transcription rate modulation due to UTR or promoter region variant and role of TFs, specifically AP1 and Sp1, in cancers or other metabolic and cardiac disorders might help further our disease knowledge and assist designing therapeutics that are more specific and effective for the disease. This evidence concerns the gene FOS and cancer.